enGene (NASDAQ:ENGN) Releases Quarterly Earnings Results, Beats Estimates By $0.06 EPS

enGene (NASDAQ:ENGN) issued its quarterly earnings results on Thursday. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.06, Zacks reports.

enGene Stock Performance

NASDAQ ENGN traded up $0.03 on Thursday, hitting $5.96. 57,410 shares of the stock were exchanged, compared to its average volume of 118,128. The company has a market capitalization of $263.53 million, a PE ratio of -3.66 and a beta of -0.78. The company has a debt-to-equity ratio of 0.09, a current ratio of 19.52 and a quick ratio of 19.52. The business’s fifty day moving average is $8.18 and its 200 day moving average is $7.82. enGene has a 52 week low of $4.42 and a 52 week high of $18.40.

Insider Activity

In other enGene news, CEO Ronald Harold Wilfred Cooper bought 10,000 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The shares were acquired at an average cost of $5.70 per share, with a total value of $57,000.00. Following the acquisition, the chief executive officer now owns 10,000 shares of the company’s stock, valued at $57,000. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Growth Opportunities F. Forbion purchased 11,844 shares of the business’s stock in a transaction on Monday, October 7th. The shares were acquired at an average cost of $6.55 per share, with a total value of $77,578.20. Following the acquisition, the insider now directly owns 2,469,833 shares in the company, valued at approximately $16,177,406.15. The trade was a 0.48 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 420,965 shares of company stock valued at $2,651,103 in the last quarter. Company insiders own 13.70% of the company’s stock.

Wall Street Analysts Forecast Growth

ENGN has been the subject of a number of analyst reports. Morgan Stanley reaffirmed an “overweight” rating and set a $40.00 target price on shares of enGene in a report on Wednesday, September 11th. JMP Securities reaffirmed a “market outperform” rating and set a $18.00 price objective on shares of enGene in a research note on Friday, December 6th. Oppenheimer reiterated an “outperform” rating and issued a $30.00 price objective on shares of enGene in a report on Tuesday, September 24th. Raymond James started coverage on enGene in a report on Wednesday, November 27th. They set an “outperform” rating and a $23.00 target price on the stock. Finally, Citizens Jmp raised enGene to a “strong-buy” rating in a research note on Monday, November 18th. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $30.38.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.